DrugPatentWatch Database Preview
RAPIVAB Drug Profile
Which patents cover Rapivab, and what generic alternatives are available?
Rapivab is a drug marketed by Biocryst and is included in one NDA. There are three patents protecting this drug.
This drug has sixty-three patent family members in twenty-eight countries.
The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the peramivir profile page.
Summary for RAPIVAB
| International Patents: | 63 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 57 |
| Clinical Trials: | 2 |
| Patent Applications: | 52 |
| Drug Prices: | Drug price information for RAPIVAB |
| DailyMed Link: | RAPIVAB at DailyMed |
Generic Entry Opportunity Date for RAPIVAB
Generic Entry Date for RAPIVAB*:
Constraining patent/regulatory exclusivity:
NEW PATIENT POPULATION NDA:
Dosage:
SOLUTION;IV (INFUSION) |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for RAPIVAB
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| BioCryst Pharmaceuticals | Phase 3 |
| Johns Hopkins University | Phase 4 |
| Department of Health and Human Services | Phase 4 |
Synonyms for RAPIVAB
| (-)-(1S,2S,3R,4R)-3-[(1S)-1-(Acetylamino)-2-ethylbutyl]-4-{[amino(imino)methyl]amino}-2-hydroxycyclopentanecarboxylic Acid |
| (+/-)-Peramivir |
| (1s,2s,3r,4r)-3-((1s)-1-acetylamino-2-ethylbutyl))-4-((aminoiminomethyl)amino)-2-hydroxycyclopentane |
| (1S,2S,3R,4R)-3-((S)-1-acetamido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentane-1-carboxylic acid |
| (1S,2S,3R,4R)-3-((S)-1-Acetamido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentanecarboxylic acid |
| (1S,2S,3R,4R)-3-(1-acetaMido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentanecarboxylic acid (Peramivir) |
| (1S,2S,3R,4R)-3-[(1S)-1-(acetylamino)-2-ethylbutyl]-4-carbamimidamido-2-hydroxycyclopentanecarboxylic acid |
| (1S,2S,3R,4R)-3-[(1S)-1-acetamido-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentanecarboxylic acid |
| (1S,2S,3R,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-carbamimidamido-2-hydroxycyclopentane-1-carboxylic acid |
| (1S,2S,3R,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-carbamimidamido-2-hydroxycyclopentane-1-carboxylic acid--water (1/3) |
| (1S,2S,3R,4R)-4-carbamimidamido-3-[(1S)-1-acetamido-2-ethylbutyl]-2-hydroxycyclopentane-1-carboxylic acid |
| (1S,2S,3S,4R)-3-((S)-1-acetamido-2-ethylbutyl)-4-((diaminomethylene)amino)-2-hydroxycyclopentane-1-carboxylic acid |
| (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid |
| 229614-55-5 |
| 229614-55-5,330600-85-6,1041434-82-5(3H2O) |
| 229614-56-6 |
| 3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID |
| 3-(1'-acetylamino-2'-ethyl)butyl-4-((aminoimino)methyl)amino-2-hydroxycyclopentane-1-carboxylic acid |
| 3(R)-[1(S)-Acetamido-2-ethylbutyl]-4(R)-guanidino-2(S)-hydroxycyclopentane-1(S)-carboxylic acid |
| 330600-85-6 |
| 600P856 |
| 9ZS94HQO3B |
| AB01566838_01 |
| AB2000310 |
| ABP000969 |
| AC-22715 |
| AC1L4BWX |
| AJ-47581 |
| AK-48380 |
| AKOS016007760 |
| API0004841 |
| AX8147150 |
| BCPP000117 |
| BCX 1812 |
| BCX-1812 |
| BCX1812 |
| BCZ |
| BDBM50181441 |
| BDBM5024 |
| CHEBI:85196 |
| CHEBI:85202 |
| CHEMBL139367 |
| CP0131 |
| CS-0638 |
| Cyclopentanecarboxylic acid, 3-((1R)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1R,2R,3S,4S)-rel- |
| Cyclopentanecarboxylic acid, 3-((1S)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1S,2S,3R,4R)- |
| Cyclopentanecarboxylic acid, 3-[(1S)-1-(acetylamino)-2-ethylbutyl]-4-[(aminoiminomethyl)amino]-2-hydroxy-, (1S,2S,3R,4R)- |
| DB06614 |
| HY-17015A |
| PeramiFlu |
| Peramivir |
| Peramivir [USAN:INN] |
| Peramivir hydrate |
| Peramivir, (+/-)- |
| Rapiacta |
| RL02720 |
| RL03191 |
| RWJ 270201 |
| RWJ-270201 |
| RWJ270201 |
| S-021812 |
| SCHEMBL12795462 |
| SCHEMBL744373 |
| ST2402123 |
| UNII-9ZS94HQO3B |
| ZINC3981610 |
US Patents and Regulatory Information for RAPIVAB
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for RAPIVAB
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Romania | 121815 | Start Trial |
| Poland | 196674 | Start Trial |
| Germany | 69840674 | Start Trial |
| China | 104784166 | Start Trial |
| South Africa | 200809012 | Start Trial |
| Mexico | 2008013140 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
